CAS: 62996-74-1; (5S,6R,7R,9R)-6-Methoxy-5-Methyl-7-(Methylamino)-6,7,8,9,15,16-Hexahydro-5H,14H-17-Oxa-4B,9A,15-Triaza-5,9-Methanodibenzo[b,H]Cyclonona[jkl]Cyclopenta[e]-As-Indacen-14-One

该化合物是一种从细菌链球菌对蛋白质动脉的广谱抑制作用而闻名于其对蛋白质直流体系具有广泛分泌抑制作用的强力碱性藻类,其特点是复杂的四环结构,有助于其生物活动; Staurosporine展示了各种动脉的高度亲近性,包括参与细胞信号传输路径的动脉,使其成为研究诸如软化和细胞扩散等细胞过程的一个宝贵工具;该化合物通常用于实验室环境,调查癌症和其他疾病的机制; 其潜在的治疗用途也得到承认,尽管其使用因非选择性性质和相关毒性而受到限制; 就物理特性而言,它是一种晶状固体,在有机溶剂中可溶解,但在水中溶解性有限; 作为研究化学品,必须谨慎地处理氨酸,并遵守安全议定书,因为其潜在的生物影响.

结构式图片

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号174291-05-5 6-N-[(benzyloxy... | CAS号174291-03-3 3'-O,4'-N-carbo...

合成工艺路线路线简述

  • 合成目标产物 Staurosporine 主要起始原料 9,13-Epoxy-1H,11H-Diindolo[1,2,3-Gh:3',2',1'-Lm]Pyrrolo[3,4-J][1,7]Benzodiazonine-1,11-Dione, 2-[(3,4-Dimethoxyphenyl)Methyl]-2,3,9,10,12,13-Hexahydro-10-Methoxy-9-Methyl-, 11-(O-Methyloxime), [9S-(9α,10β,11Z,13α)]- (9CI)
  • (文献来源)合成步骤主要原料 9,13-Epoxy-1H,11H-Diindolo[1,2,3-Gh:3',2',1'-Lm]Pyrrolo[3,4-J][1,7]Benzodiazonine-1,11-Dione, 2-[(3,4-Dimethoxyphenyl)Methyl]-2,3,9,10,12,13-Hexahydro-10-Methoxy-9-Methyl-, 11-(O-Methyloxime), [9S-(9α,10β,11Z,13α)]- (9Ci)

海关参考信息

专利信息


专利号:US-10973847-B2
优先权日:2017-06-30
标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

专利号:US-2017283878-A1
优先权日:2015-12-11
标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
权利人:ACADEMIA SINICA
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

专利号:US-11155562-B2
优先权日:2014-06-30
标 题 :Synthesis of halichondrin analogs and uses thereof
发明人:KISHI YOSHITO; UEDA ATSUSHI; YAMAMOTO AKIHIKO; KATO DAISUKE
权利人:HARVARD COLLEGE
摘要:The present invention provides halichondrin analogs, such as compounds of Formula (I). The compounds may bind to microtubule sites, thereby inhibiting microtubule dynamics. Also provided are methods of synthesis, pharmaceutical compositions, kits, methods of treatment, and uses that involve the compounds for treatment of a proliferative disease (e.g., cancer). Compounds of the present invention are particularly useful for the treatment of metastatic breast cancer, non-small cell lung cancer, prostate cancer, and sarcoma. The included methods of synthesis are useful for the preparation of compounds of Formula (I)-(III) along with naturally occurring halicondrins (e.g., halichondrin B & C, norhalichondrin A, B, & C, and homohalichondrin A, B, & C). Also included are methods for interconverting between the halichondrins, norhalichondrins, and homohalichondrins and their unnatural epimers at the C38 ketal stereocenter through the use of an acid-mediated equilibration.

专利号:WO-9614060-A1
优先权日:1994-11-04
标题 :Use of receptor agonists to stimulate superoxide dismutase activity
发明人:MARKLUND STEFAN L; STRAALIN PONTUS
权利人:MARKLUND STEFAN L; STRAALIN PONTUS
摘要:The present invention relates to the use of a substance for the manufacture of a composition for stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells. In particular, the invention relates to the use of a substance for the manufacture of a composition for prophylaxis or treatment of a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical. Further, the invention relates to a method for determining the effect of a substance with respect to stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells and to substances which have been selected by said method. Within the scope of the invention is a method of preventing, diminishing, controlling or inhibiting a disease or disorder connected with the presence or formation of superoxide radicals and other toxic intermediates derived from the superoxide radical in a patient who has been established to have a high risk of developing a such disease or disorder, or who has developed a such disease or disorder, the method comprising administering an effective amount of a substance which is capable of stimulating the release of EC-SOD from cells or stimulating the synthesis of EC-SOD in cells.

专利号:US-2025206743-A1
优先权日:2022-03-25
标 题:Tyk2 inhibitor synthesis and intermediates thereof
发明人:MASSE CRAIG E; PHADKE AVINASH S; LAWSON JON P; LEVY STUART; YANG XIAOWEI; WU GUISHENG; FAN SHUFENG
权利人:TAKEDA PHARMACEUTICALS CO
摘要:Described herein are methods of synthesis of a tyrosine-protein kinase 2 (TYK2) inhibitor and to intermediate compounds of the synthesis and methods of making the intermediates. Also provided are pharmaceutically acceptable compositions including compounds prepared by the synthetic method and methods of treating disorders using the same.
台州市科瑞生物技术有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.pharm-intermediates.com
企业联系电话:0576-88813233👤
📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
联系人:金崇光
电话:0576-88813233
手机:13396860566
传真:0576-88813233
邮箱:sales@pharm-intermediates.com
通信地址: 台州市开发大道东段288号
邮编: 318000
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:台州市开发大道东段288号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
福建科瑞药业有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.fjim.org.cn/
电话: (0591)83470739👤
📞福建科瑞药业有限公司 ⚠️参考联系方式

销售电话:(0591)83470739
邮箱:Lihua.Xiao@kerui.microport.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
湖北威德利化学科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.widelychemical.com
企业联系电话:13385289472👤
📞湖北威德利化学科技有限公司 ⚠️参考联系方式
联系人:赵方
电话:13385289472
手机:13385289472
传真:027- 59222918
邮箱:z13385289472@163.com
通信地址: 湖北省武汉市硚口区解放大道204号
邮编: 430033
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:湖北省武汉市硚口区解放大道204号
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Hussein BRM, Mohammed HH, Ahmed EA, Alshazly O, Mohamed MFA, Omran OA. Design, synthesis, and anti-breast cancer activity evaluation of novel 3-cyanopyridine derivatives as PIM-1 inhibitors. Mol Divers. 2024 Nov 9. doi: 10.1007/s11030-024-11010-8. Epub ahead of print. 19(11):e0308647. doi: 10.1371/journal.pone.0308647.
3: Liu W, Kuai Y, Wang D, Chen J, Xiong F, Wu G, Wang Q, Huang W, Qi Y, Wang B, Chen Y. PPM1G Inhibits Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter. Adv Sci (Weinh). 2024 Oct
30:e2407323. doi: 10.1002/advs.202407323. Epub ahead of print. 85(7):e70009. doi: 10.1002/ddr.70009. 25(1):24. doi: 10.1186/s12860-024-00521-9.

合成参考文献


参考文献:10.4161/cbt.4.11.2286
摘要:Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther. 2005 Nov;4(11):1275–84. doi: 10.4161/cbt.4.11.2286.
参考文献:10.1016/j.bmc.2010.01.056
摘要:Mashkani B, Griffith R, Ashman LK. Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem. 2010 Mar 01;18(5):1789–97. doi: 10.1016/j.bmc.2010.01.056.
参考文献:10.3233/jad-2010-1281
摘要:Ji L, Chauhan A, Chauhan V. Upregulation of cytoplasmic gelsolin, an amyloid-beta-binding protein, under oxidative stress conditions: involvement of protein kinase C. J Alzheimers Dis. 2010;19(3):829–38. doi: 10.3233/jad-2010-1281.
参考文献:10.3233/jad-2010-1294
摘要:Liu XA, Liao K, Liu R, Wang HH, Zhang Y, Zhang Q, Wang Q, Li HL, Tian Q, Wang JZ. Tau dephosphorylation potentiates apoptosis by mechanisms involving a failed dephosphorylation/activation of Bcl-2. J Alzheimers Dis. 2010;19(3):953–62. doi: 10.3233/jad-2010-1294.
参考文献:10.4196/kjpp.2008.12.1.31
摘要:Jung S, Lee Y, Han S, Kim Y, Nam T, Ahn D. Lysophosphatidylcholine Increases Ca2+Current via Activation of Protein Kinase C in Rabbit Portal Vein Smooth Muscle Cells. Korean J Physiol Pharmacol. 2008;12(1):31. doi: 10.4196/kjpp.2008.12.1.31.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知